Benign prostatic hyperplasia efficacy meta-analysis safety systematic review

Anticoagulant therapy benign Prostatic Hyperplasia

Phosphodiesterase Type 5 Inhibitors Tamsulosin Benign Prostatic Hyperplasia Lower Urinary Tract Symptoms Meta-Analysis

Imidafenacin Overactive Bladder Benign Prostatic Hyperplasia Meta-Analysis

Aged Aged 80 and over Humans Male Middle Aged Outcome Assessment Health Care Plant Extracts/administration & dosage Prostatic Hyperplasia/*drug therapy Serenoa Tamsulosin/administration & dosage Urological Agents/administration & dosage *Serenoa repens *benign prostatic hyperplasia *meta-analysis *randomized controlled trials *tamsulosin conflicts of interest with respect to the research authorship and/or publication of this article.

BCG Bladder Bladder Neoplams Cancer Cystectomie Cystectomy Cytologie Urinaire Cytology Medical Subject Headings (MeSH) Carcinome Urothélial Medical Subject Headings (MeSH) Urothelial Carcinoma Survie Survival Tumeurs De La Vessie Vessie.

5-alpha Reductase Inhibitors/*administration & dosage Adrenergic alpha-1 Receptor Antagonists/*administration & dosage Drug Therapy Combination Dutasteride/*administration & dosage Erectile Dysfunction/chemically induced/diagnosis Humans Male Prostatic Hyperplasia/diagnosis/*drug therapy/epidemiology Randomized Controlled Trials as Topic/methods Tamsulosin/*administration & dosage Treatment Outcome Benign prostatic hyperplasia Dutasteride Meta-analysis Randomized controlled trials Tamsulosin published studies thus no ethical approval and patient consent are required. CONSENT FOR PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Urothelial Carcinoma Bladder Cytology Bladder Neoplams Cancer BCG Cystectomy Survival

Humans Biomarkers Tumor *Carcinoma in Situ/diagnosis *Carcinoma Transitional Cell/pathology Hyaluronan Receptors/metabolism Keratin-20/analysis/metabolism Ki-67 Antigen/metabolism Tumor Suppressor Protein p53/analysis/metabolism Urinary Bladder *Urinary Bladder Neoplasms/pathology Urothelium/chemistry/metabolism/pathology Bladder carcinoma Carcinoma in situ Carcinoma vesical Displasia Dysplasia Immunomarkes Inmunomarcadores

Humans Palliative Care Prospective Studies Quality of Life Retrospective Studies *Urinary Bladder Neoplasms/radiotherapy Radiotherapy bladder cancer bleeding palliation

Animals *Cheese Cohort Studies Dairy Products Diet Humans Milk Risk Factors *Urinary Bladder Neoplasms/epidemiology/etiology Yogurt

Adult Female *Hormones/adverse effects Humans Menopause Middle Aged Prospective Studies *Reproductive History Risk Factors *Urinary Bladder Neoplasms/epidemiology Bladder cancer Health Study Nurses’ females hormones reproductive factors

Anti-Bacterial Agents/therapeutic use Antibiotic Prophylaxis Humans Meta-Analysis as Topic Postoperative Complications/drug therapy Systematic Reviews as Topic *Urinary Bladder Neoplasms/drug therapy/surgery *Urinary Tract Infections/drug therapy/prevention & control Antibiotic resistance Antibiotics Antimicrobial stewardship Bacteriuria Endourological surgery Guideline Recommendation Transitional cell carcinoma Urothelium cell carcinoma

Biomarkers Tumor *Cystoscopy *Cytodiagnosis Early Detection of Cancer Humans Prospective Studies Reproducibility of Results Retrospective Studies Sensitivity and Specificity Urinary Bladder Neoplasms/complications/*diagnosis/pathology Urinary Bladder Neurogenic/*complications (MeSH): neurogenic bladder bladder cancer cystoscopy screening urinary cytology

Chemoradiotherapy/*methods Combined Modality Therapy Cystectomy/*adverse effects/methods Disease-Free Survival Female Humans Male Middle Aged Neoplasm Metastasis Robotic Surgical Procedures/*adverse effects/methods Treatment Outcome Urinary Bladder Neoplasms/diagnostic imaging/*therapy Bladder cancer Cystectomy Multi-modality treatment Port-site metastasis Rare complications